Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Misonidazole SCHEMBL2168353 | 0.91 | KMT2A (0.56) | KMT2ALMNATHRBCYP2C19HPGD | |
| Misonidazole SCHEMBL18770100 | 0.89 | KMT2A (0.54) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL12396375 | 0.87 | KMT2A (0.78) | KMT2ALMNATHRBCYP2C19HPGD | |
| Misonidazole SCHEMBL2833961 | 0.86 | KMT2A (0.51) | KMT2ALMNATHRBCYP2C19HPGD | |
| Misonidazole SCHEMBL9762481 | 0.86 | KMT2A (0.51) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL9441423 | 0.85 | KMT2A (0.62) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL6275185 | 0.85 | KMT2A (0.55) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL16367290 | 0.84 | KMT2A (0.60) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL2358150 | 0.84 | KMT2A (0.71) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL29287184 | 0.84 | KMT2A (0.63) | KMT2ALMNATHRBCYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6585 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4687863-A1 | RADIOPROTECTION BY INHIBITION OF SUPEROXIDE DISMUTASE 1 | Deutsches Krebsforschungszentrum (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4676551-A1 | RADIATION SPACER HYDROGELS, METHODS OF FORMING, AND METHODS OF USE | Clearstream Technologies Limited (IE) | 2026-01-14 | — | — | EP | claimed |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-04 | — | — | US | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250345629-A1 | JOINT OPTIMIZATION OF RADIONUCLIDE AND EXTERNAL BEAM RADIOTHERAPY | REFLEXION MEDICAL INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250222066-A1 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-07-10 | — | — | US | claimed |
| EP-4547023-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | University of Utah Research Foundation (US) | 2025-05-07 | — | — | EP | claimed |
| WO-1991013633-A1 | IMPROVEMENTS RELATING TO IMMUNORADIOTHERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1991-09-19 | — | — | WO | claimed |
| US-5026694-A | Antitumor agents | THE BRITISH COLUMBIA CANCER FOUNDATION (CA) | 1991-06-25 | — | — | US | claimed |
| US-4978332-A | Reduced effect on cells distant from the site | MATRIX PHARMACEUTICAL, INC. (US) | 1990-12-18 | — | — | US | claimed |
| US-4921963-A | Platinum complexes with one radiosensitizing ligand | BRITISH COLUMBIA CANCER FOUNDATION (CA) | 1990-05-01 | — | — | US | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0335966-A4 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS. | MATRIX PHARMA INC (US) | 1990-02-20 | — | — | EP | claimed |
| EP-0335966-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-10-11 | — | — | EP | claimed |
| EP-0330201-A2 | Method of enhancing the effect of cytotoxic agents | NEORX CORPORATION (US) | 1989-08-30 | — | — | EP | claimed |
| WO-1989002734-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-04-06 | — | — | WO | claimed |
| EP-0287317-A2 | Platinum complexes with one radiosensitizing ligand | THE BRITISH COLUMBIA CANCER FOUNDATION (CA) | 1988-10-19 | — | — | EP | claimed |